Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimta LabsBOM:524394 +3.58%84 Current Ratio is 0.00 as of Jun. 2026. GuruFocus rates BOM:524394 with a GF Score™ of 84/100 and a GF Value™ of ₹495.16 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 213 Medical Diagnostics & Research companies, Vimta Labs ranks better than 71.83% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Vimta Labs's current ratio for the quarter that ended in Jun. 2026 was 0.00.
Vimta Labs has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Vimta Labs has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Vimta Labs's Current Ratio or its related term are showing as below:
BOM:524394'
s Current Ratio Range Over the Past 10 Years
Min: 1.17 Med: 2.15 Max: 3.43
Current: 3.43
During the past 13 years, Vimta Labs's highest Current Ratio was 3.43. The lowest was 1.17. And the median was 2.15.
BOM:524394's Current Ratio is ranked better than 71.83% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.12
vs BOM:524394: 3.43
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Vimta Labs Current Ratio Related Terms
Vimta Labs Current Ratio Historical Data
* Premium members only.
The historical data trend for Vimta Labs's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524394 vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Vimta Labs's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimta Labs Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimta Labs's Current Ratio distribution charts can be found below:
* The bar in red indicates where Vimta Labs's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimta Labs (BOM:524394) has a Current Ratio of 0.00 as of Jun. 2026. Over the past decade, Vimta Labs' Current Ratio has ranged from 1.17 to 3.43. According to the industry distribution chart, Vimta Labs ranks #60 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 28.2%.
Is Vimta Labs' Current Ratio too high?
Vimta Labs' current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 3.43. Based on the distribution chart, Vimta Labs ranks #60 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Vimta Labs has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vimta Labs' Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimta Labs ranks #60 out of 213 companies for Current Ratio. This puts Vimta Labs in the upper half of its industry. The industry median Current Ratio is 2.12. Historically, Vimta Labs' own Current Ratio has ranged from 1.17 to 3.43 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.12, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimta Labs's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimta Labs stock overvalued right now?
Based on GuruFocus' analysis, Vimta Labs (BOM:524394) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹495.16, compared to a current price of ₹641.20 — trading 29.5% above its estimated fair value. The current Current Ratio is 0.00. Vimta Labs' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Vimta Labs (BOM:524394), the current Current Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimta Labs (BOM:524394) Overvalued in 2026?
Based on GuruFocus' analysis, Vimta Labs stock appears to be overvalued.
The current stock price of ₹641.20 is trading 29.5% above its estimated GF Value™ of ₹495.16.
GuruFocus considers Vimta Labs to be Modestly Overvalued.
Key valuation signals for BOM:524394:
Current Ratio: 0.00
GF Value™: ₹495.16 vs. price of ₹641.20 (29.5% above fair value)
No single metric tells the full story. See the BOM:524394 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimta Labs Ltd is a comprehensive contract research and testing organization, providing a wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and many other industries. Its services portfolio includes testing and contract research services in the fields of clinical research, pre-clinical research, clinical diagnostics, biopharma services, analytical testing, research and environmental studies, and Others. It has only one reportable segment namely Contract Research and Testing Services which generates the revenue.
84GF Score
Get the complete analysis for BOM:524394
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524394 has been successfully added to your 
